Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases.
The present report critically reviews the rationale, experimental and clinical effectiveness and limits of anti-CD4 monoclonal antibody (mAb) therapy. References are also made to a novel approach involving active immunotherapy and an anti-idiotypic mAb bearing the internal image of human CD4 antigen. Preliminary observations concerning the effects of this treatment in one patient with rheumatoid arthritis and in one patient with systemic lupus erythematosus are reported.
Perosa
F
F
Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari Medical School, Italy.
Scudeletti
M
M
Imro
M A
MA
Dammacco
F
F
Luccarelli
G
G
Indiveri
F
F
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy*; D015704:CD4 Antigens / Q000276:immunology*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens